Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
dihydroergocornine
Class :
Ergot alkaloids
Brand Name :
N/A
Synonyms :
dihydroergocornine
Class :
Ergot alkaloids
Dosage Forms & StrengthsÂ
Intravenous injectionÂ
0.25mgÂ
0.50mgÂ
0.75mgÂ
0.45
mg
Solution
Intravenous (IV)
0.45mg i.v., followed in 5 minutes by an increase of 270ml in the vital capacity and 37 liters per minute in the maximum ventilation
Data not availableÂ
Refer to adult dosingÂ
acrivastine and pseudoephedrineÂ
may increase the vasoconstrictive effect of alpha/beta agonists
may decrease the vasodilatory effect when combined with nitroglycerin
they increase the effect of vasoconstriction of alpha-1 agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may increase the vasoconstriction effect of sympathomimetic drugs
may increase the vasoconstriction effect of sympathomimetic drugs
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists (Triptans)
may enhance the concentration of serum when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with dihydroergotamine
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may have an increasingly adverse effect when combined with ergot derivatives
may have an increasingly adverse effect when combined with ergot derivatives
may have an increased serotonergic effect when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
ergot derivatives increase the toxicity of bromocriptine
it increases the concentration of ergot derivatives in serum
ergot Derivatives may enhance the serotonergic effect of serotonergic Agents
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may have an increased serotonergic effect when combined with serotonergic agents
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
bazedoxifene/conjugated estrogens
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
the serum levels of dihydroergocornine may be increased
the rate of metabolism of dihydroergocornine may be increased
the rate of metabolism of acalabrutinib may be reduced with dihydroergocornine
the vasoconstricting activity of dihydroergocornine may be increased with acebutolol
the risk of hypertension may be increased
the serum levels of dihydroergocornine may be increased
the rate of metabolism of astemizole can be reduced
the severity of hypertension may be increased
the antihypertensive activity of bepridil may be reduced
the rate of metabolism of dihydroergocornine may be increased
the vasoconstricting activity of zolmitriptan may be increased
the therapeutic activity of dihydroergocornine may be reduced
When indisulam is used together with dihydroergocornine, this leads to a reduction in dihydroergocornine metabolism
When dihydroergocornine is used together with oleandomycin, this leads to enhanced concentration serum of dihydroergocornine
When dihydroergocornine is used together with ridaforolimus, this leads to enhanced concentration serum of dihydroergocornine
it may increase the effect of serotonergic agents
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the vasoconstrictive effect of beta blockers
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the serum concentration
may increase the vasoconstricting effect
may have an increasingly adverse effect when combined with ergot derivatives
may have an increased hypertensive effect when combined with ergot derivatives
it increases the effect of hypertension of ergot derivatives
may enhance the serum concentration of Ergot Derivatives
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Endothelin antagonists
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
bazedoxifene/conjugated estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Vasodilators
Actions and spectrum:Â
Dihydroergocornine is said to have both peripheral and central effects. The vasodilator center’s stimulation is associated with a drop in blood pressure. Dihydroergocornine has been shown to have sympatholytic and adrenolytic effects.
Dihydroergocornine has an inhibitory effect on both noradrenaline and serotonin receptors, and it appears to be particularly effective at preventing noradrenaline overflow caused by stimulation.Â
Frequency not definedÂ
Black Box Warning Â
Not availableÂ
Contraindication/Caution:Â
Contraindication:Â
Not availableÂ
Pregnancy consideration:Â Â
Limited data availableÂ
Lactation:Â Â
Limited data availableÂ
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
Limited data availableÂ
Pharmacodynamics:Â
Pharmacokinetics:Â
Limited data availableÂ
AbsorptionÂ
DistributionÂ
MetabolismÂ
Elimination and excretionÂ
Half-life:Â
Administration:Â
Dihydroergocornine is administered intravenouslyÂ
Patient information leafletÂ
Generic Name: dihydroergocornine Â
Why do we use dihydroergocornine?Â
Dihydroergocornine, an alkaloid of ergot, is used in the treatment of bronchial asthma.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
